- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Castration resistant carcinoma of the prostate
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1063KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 116KB)
Darolutamide – July 2021
Darolutamide: Tablet 300 mg; Nubeqa®
Last updated
29 October 2021